Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Haematologica

Volumn 99, Issue 9, 2014, Pages

  Montillo, Marco ^a   Tedeschi, Alessandra ^a   Gaidano, Gianluca ^b   Coscia, Marta ^c   Petrizzi, Valeria Belsito ^d   Orlandi, Ester ^e   Cascavilla, Nicola ^f   Ghia, Paolo ^g   Motta, Marina ^h   Gallamini, Andrea ⁱ   Frustaci, Anna Maria ^a   Rossi, Davide ^b   De Paoli, Lorenzo ^b   Nichelatti, Michele ^a   Morra, Enrica ^a   Massaia, Massimo ^c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Azienda Ospedaliero Universitaria Maggiore della Carità   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d General Hospital   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h SPEDALI CIVILI   (Italy)

ⁱ Centro Studi Professioni Sanitarie   (Italy)

Author keywords

Bendamustine; Effective treatment; Relapsed refractory chronic lymphocytic leukemia

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; ALKYLATING AGENT; CHLORMETHINE DERIVATIVE; DRUG COMBINATION; MONOCLONAL ANTIBODY;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LETTER; LEUKEMIA RELAPSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84907374559     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.106740     Document Type: Letter

References (15)

1. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554-3561.
2. Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M, et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood. 2011;118(15):4079-4085.
3. Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, et al. Fludarabine and cyclophosphamide in combination with alem-tuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2012;26(12):2549-2552.
4. Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012;119(22):5104-5110.
5. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378-4384.
6. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multi-center phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-3566.
7. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209-3216.
8. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v3.0. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
9. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
10. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
11. Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, et al. NOTCH1, SF3B1, end TP53 mutations in Fludarabine-refractory CLL patients treated with Alemtuzumab: results from the CLL2H trial of GCLLSG. Blood. 2013;122(7):1266-1270.
12. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoim-munotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016-3024.
13. Cortelezzi A, Sciumè M, Liberati AM, Vincenti D, Cuneo A, Reda G, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multicenter phase II trial. Leukemia. 2014;28(3):642-648.
14. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011;12(13):1204-1213.
15. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(19):1756-1765.